Daraxonrasib Shows Promising Activity in RAS-Mutant Lung Cancer: NEJM

Coverage, in order

1. 5d ago
   
   Medical Dialogues India obscure randomized trialpeer-reviewed

   Daraxonrasib Shows Promising Activity in RAS-Mutant Lung Cancer: NEJM

   USA: The oral RAS inhibitor daraxonrasib (Rasonque) , recently approved by the FDA for metastatic pancreatic ductal adenocarcinoma, demonstrated promising efficacy in previously treated patients with metastatic RAS-mutant non-small cell lung cancer (NSCLC) . In a phase I/II trial, the drug achieved…

Alivewire groups outlets reporting the same story. Each headline links to the outlet that wrote it; nothing is republished here.